XTX Topco’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

XTX Topco’s Portfolio JNCE Stock Details JNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-78,190	Closed	-$145K	–	1988
2023 Q1	$145K	Buy	+78,190	New	+$96.9K	0.03%	1033
2022 Q3	–	Sell	-37,362	Closed	-$113K	–	1481
2022 Q2	$113K	Buy	+37,362	New	+$182K	0.05%	618
2021 Q3	–	Sell	-29,928	Closed	-$204K	–	1173
2021 Q2	$204K	Buy	+29,928	New	+$249K	0.07%	554

Other funds holding JNCE

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

XTX Topco's JNCE Position: Q2 2023 in Review

XTX Topco sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q2 2023, closing a stake of 78,190 shares — an estimated $145K sold.

XTX Topco first reported a position in JNCE in Q2 2021 and held it in 3 quarters. The position peaked at $204K in Q2 2021. 1 fund tracked by Wall St. Rank holds JNCE as of Q2 2023.

XTX Topco reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
XTX Topco sold 78,190 Jounce Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $145K.
XTX Topco first reported a position in Jounce Therapeutics, Inc. Common Stock in Q2 2021 and held it in 3 quarters.
XTX Topco's Jounce Therapeutics, Inc. Common Stock position peaked at $204K in Q2 2021.
1 fund tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q2 2023.

Based on XTX Topco's 13F filing for Q2 2023, filed 14 Aug 2023.